The Medicines Patent Pool (MPP) announced a new licence and technology transfer agreement with Pharco Pharmaceuticals for ravidasvir (RAV), an investigational direct-acting antiviral (DAA) with the potential of working across all six major hepatitis C genotypes.
“If successfully developed, ravidasvir could help treat millions of hepatitis C patients and we are pleased to work with Pharco to ensure the availability of affordable versions,” said Greg Perry, executive director of the Medicines Patent Pool.
The Medicines Patent Pool is a United Nations-backed public health organisation working to increase access to HIV, hepatitis C and tuberculosis treatments in low and middle income countries.
The agreement, signed on the sidelines of the International Liver Congress in Amsterdam, will enable competitive supply of RAV in low and middle income countries (LMICs) including high prevalence nations Russia, Ukraine, Egypt and Iran.
Sherine Helmy, CEO of Pharco Pharmaceuticals, said: “Chronic hepatitis C affects approximately 71 million people globally, with Egypt suffering from one of the highest burdens.
“RAV, in combination with other hepatitis C treatments, could support new national as well as global goals to eliminate the virus.”
The MPP-Pharco licence for RAV is royalty bearing over net sales in the licensed territory — 4% in low income nations and 7% for middle income countries.
Pharco Pharmaceuticals is waiving royalties for paediatric formulations. The licence includes a technology transfer to MPP’s sub licensees.